RecruitingPhase 2NCT05236582

Herombopag for Chemotherapy-induced Thrombocytopenia

Studying Anorectal malformation

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Principal Investigator
Lei Zhang, MD
Chinese Academy of Medical Science and Blood Disease Hospital
Intervention
Herombopag(drug)
Enrollment
50 target
Eligibility
18 years · All sexes
Timeline
20222025

Study locations (1)

Collaborators

Tianjin Medical University Cancer Institute and Hospital · Tianjin Medical University Second Hospital · Tianjin Third Central Hospital · Tianjin People's Hospital · Henan Cancer Hospital · The Second Affiliated Hospital of Kunming Medical University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05236582 on ClinicalTrials.gov

Other trials for Anorectal malformation

Additional recruiting or active studies for the same condition.

See all trials for Anorectal malformation

← Back to all trials